Abstract

Myosin storage myopathy is a protein aggregate myopathy associated with the characteristic subsarcolemmal accumulation of myosin heavy chain in muscle fibers. Despite similar histological findings, the clinical severity and age of onset are highly variable, ranging from no weakness to severe impairment of ambulation, and usually childhood-onset to onset later in life. Mutations located in the distal end of the tail of slow/ß-cardiac myosin heavy chain are associated with myosin storage myopathy. Four missense mutations (L1793P, R1845W, E1883K and H1901L), two of which have been reported in several unrelated families, are located within or closed to the assembly competence domain. This location is critical for the proper assembly of sarcomeric myosin rod filaments. To assess the mechanisms leading to protein aggregation in myosin storage myopathy and to evaluate the impact of these mutations on myosin assembly and muscle function, we expressed mutated myosin proteins in cultured human muscle cells and in the nematode Caenorhabditis elegans. While L1793P mutant myosin protein efficiently incorporated into the sarcomeric thick filaments, R1845W and H1901L mutants were prone to formation of myosin aggregates without assembly into striated sarcomeric thick filaments in cultured muscle cells. In C. elegans, mutant alleles of the myosin heavy chain gene unc-54 corresponding to R1845W, E1883K and H1901L, were as effective as the wild-type myosin gene in rescuing the null mutant worms, indicating that they retain functionality. Taken together, our results suggest that the basis for the pathogenic effect of the R1845W and H1901L mutations are primarily structural rather than functional. Further analyses are needed to identify the primary trigger for the histological changes seen in muscle biopsies of patients with L1793P and E1883K mutations.

Highlights

  • The class II conventional muscle myosin exists as a hexameric protein composed of two myosin heavy chain (MyHC) subunits and two pairs of non-identical light chain subunits [1, 2]

  • We examined the behaviour of selected slow/β-cardiac MyHC mutations associated with myosin storage myopathy (MSM) in a physiologically relevant context by transfecting the human muscle cells in culture

  • While WT and L1793P mutant myosin proteins formed similar punctate myosin structures distributed through the cytoplasm of transfected myoblasts, formation of dense bodies appeared to be the dominant phenotype of the R1845W mutant protein (Fig 1)

Read more

Summary

Introduction

The class II conventional muscle myosin exists as a hexameric protein composed of two myosin heavy chain (MyHC) subunits and two pairs of non-identical light chain subunits [1, 2]. Myosin Storage Myopathy and Mechanisms coiled-coil interaction along the long tail domains. Dimerization of two MyHCs results in a polar structure with two distinct regions, which provide the motor and filament-forming functions (S1A Fig). The amino terminus forms a globular head domain that binds to actin and ATP, which is required for motor activity [3]. The elongated α-helical coiled-coil C-terminal rod domain exhibits filament-forming properties that assemble into thick filaments of the sarcomeres located in the A-band [1] (S1A Fig). MyHC is the major constituent of the sarcomeric thick filaments, and has an essential structural function. Myosin binding protein C (MyBPC), located in the central region of the A-band, promotes the polymerisation of the sarcomeric thick filaments

Methods
Results
Conclusion

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.